How Ca1.2-bound verapamil blocks Ca influx into cardiomyocyte: Atomic level views.

Wei Li, Ganggang Shi

Journal: Pharmacological research 2019;139():153-157

PMID: 30447294

Abstract

The first clinically used antiarrhythmic, antianginal and anti-hypertensive phenylalkylamine, verapamil's cardiovascular activity is inextricably linked to its ability to antagonize Ca overload via blocking Ca1.2, a cardiac L-type Ca channel of undisputed physiological and pharmacological importance in cardiovascular disorders such as myocardial ischemia-reperfusion injury. From a structural point of view, however, the action mechanism of verapamil is still elusive. Therefore, incorporating previous findings for verapamil and Ca1.2, this review article puts forward two experimental data-derived and -supported 3D structure models for Ca1.2's α subunit and its verapamil-bound form. Furthermore, this article suggests three biophysical mechanisms, namely competitive binding, steric hindrance and electrostatic repulsion, towards an atomic level understanding of how verapamil blocks the L-type Ca current mediated by Ca1.2 in reality, which can be useful for the design and development of next-generation Ca antagonists to provide safer and more effective treatment of cardiovascular diseases.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Address: Department of Pharmacology, Shantou University Medical College, No. 22, Xinling Road, Shantou City, Guangdong Province, PR China.; Department of Pharmacology, Shantou University Medical College, No. 22, Xinling Road, Shantou City, Guangdong Province, PR China. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.